Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www1.apotex.com/ca
Number of Employees: 8,000
Year Founded: 1974
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Apotex Inc., a pharmaceutical company, researches, develops, and manufactures generic pharmaceuticals. The company manufactures generic pharmaceutical products in various dosages and formats. It also provides business resources, such as Apotex 360 and Apotex Concierge Service. In addition, the company offers services, which include DISpedia, ApoAssist, and Apo-Rosiglitazone services for healthcare professionals and patients. It exports its products to countries across the globe. The company was founded in 1974 and is based in Toronto, Canada with additional locations in USA, Belgium, the Czech Republic, Poland, Spain, Australia, India, New Zealand, and the Netherlands. Apotex Inc. operates as a subsidiary of Apotex Pharmaceutical Holdings Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
 3,628.4
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 8,000
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Fahner, Gordon 
Senior Vice President of Global Finance
McNicoll, Andrew 
Senior Vice-President of Global Quality & Compliance
Berman, Jordan 
Vice President of Global Corporate Affairs, Business Transformation & Strategic Planning
Campbell, Joanne 
Senior VP & Chief Human Resources Officer
Hardwick, Peter 
Chief Commercial Officer & Executive VP
Krishnan, Kiran 
Senior Vice President of Global Regulatory Affairs
Liberty, Steven M.
EVP of Global Supply & Technical Operations
Shelley, Ray 
Senior Vice President of Commercial Operations-Canada & Caribbean
Heselton, Mark
President of Apotex International
Paton, Pere 
President of Global API


Primary Industry Classification
Pharmaceuticals


Primary Office Location
150 Signet Drive | Toronto, ON | M9L 1T9 | Canada
Fax: 800 609 9444

Parent Company
Apotex Pharmaceutical Holdings Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Lareq Pharma S.L.
Lareq Pharma S.L. manufactures pharmaceutical products. The company was founded in 1984 and is based in Madrid Spain. As of December 5, 2007, Lareq Pharma S.L. is a subsidiary of Apotex, Inc.

Europe
Pharmaceuticals
-
-
-
Topgen, E.S.V.
Topgen, E.S.V. manufactures pharmaceutical products and is based in Brussels, Belgium. As of November 15, 2007, Topgen, E.S.V. is a subsidiary of Apotex, Inc.

Europe
Pharmaceuticals
-
-
-
ApoPharma Inc.
ApoPharma Inc. develops medicine for the treatment of Thalassemia. The company was founded in 2004 and is based in Toronto, Canada. ApoPharma Inc. operates as a subsidiary of Apotex Inc.

United States and Canada
Pharmaceuticals
14.00
-
-
ApoPharma USA Inc.
ApoPharma USA Inc. operates as a drug company for hematology and neurodegeneration therapeutic areas. The company was founded in 2010 and is based in Weston, Florida. ApoPharma USA Inc. operates as a subsidiary of Apotex Inc.

United States and Canada
Pharmaceuticals
-
-
-
Apotex Corp.
Apotex Corp. develops, manufactures, markets and distributes a broad range of pharmaceutical products. It offers tablets, capsules, injections, and nasal sprays. The company also distributes pharmaceutical products of other manufacturers. In addition, it offers drugs information to healthcare professionals. Apotex Corp. offers its products to pharmacy and healthcare facilities in Canada, the United States, and internationally. The company offers its products through distributors worldwide. Apotex Corp. was incorporated in 1992 and is based in Weston, Florida with facilities in North America and other parts of the world. Apotex Corp. operates as a subsidiary of Apotex, Inc.

United States and Canada
Pharmaceuticals
104.00
-
-
Apotex Pharmachem Inc.
APOTEX PHARMACHEM INC. engages in the research and development, and manufacture of active pharmaceutical ingredients. It offers products in various categories, such as anti-bacterial, anti-diabetics, anti-viral, cancer, cardiovascular, CNS, gastrointestinal, ophthalmic, osteological, pain/inflammation, psychotherapeutic, respiratory, urological, and others. APOTEX PHARMACHEM INC. was formerly known as Brantford Chemicals, Inc. The company was founded in 1974 and is based in Brantford, Canada with facilities in Canada, India, Mexico, and China. APOTEX PHARMACHEM INC. operates as a subsidiary of Apotex Inc.

United States and Canada
Pharmaceuticals
531.00
-
-
Protein, S.A. De C.V.
Mfg Medicinal/Botanical Products

Latin America and Caribbean
Pharmaceuticals
48.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-13-2019
Jul-10-2019
Merger/Acquisition
Seller
Certain Global Rights And Assets Of Peg-Filgrastim And Filgrastim of Apotex Inc.
Accord Healthcare Limited,Intas Pharmaceuticals Limited
Apotex Inc.
-
Jul-14-2018
Feb-11-2019
Merger/Acquisition
Seller
Subsidiaries in the Netherlands, Belgium, Spain, Poland and Czech Republic
Agile Pharma B.V.
Apotex Inc.
86.36
May-09-2018
Jul-10-2019
Merger/Acquisition
Seller
Apotex Pty Ltd.
Arrotex Australia Group
Apotex Inc.
-
Dec-11-2013
Feb-21-2014
Merger/Acquisition
Seller
Emergent BioSolutions Canada Inc.
Emergent BioSolutions Inc. (NYSE:EBS)
Apotex Holdings, Inc.,Sherman Foundation, Endowment Arm,Apotex Inc.,Apotex Foundation, Endowment Arm
219.02
May-21-2013
Jul-1-2013
Merger/Acquisition
Seller
Diocle S.p.A.
Charterhouse Capital Partners LLP
Apotex Inc.,Chiesi Farmaceutici S.p.A.,Zambon Company S.p.A.
387.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-26-2023
Company Conference Presentations
Apotex Inc. Presents at 2023 CSPS Annual Symposium, May-26-2023 09:00 AM
Dec-23-2022
Lawsuits & Legal Issues
Vanda Pharmaceuticals Inc. Announces Update on Suit Brought Against Teva Pharmaceuticals USA, Inc. and Apotex Inc. Asserting Infringement of Patents Covering HETLIOZ® (Tasimelteon) 20 mg Capsules
Dec-16-2022
Lawsuits & Legal Issues
Vanda Pharmaceuticals Inc. Provides an Update to HETLIOZ® ANDA Litigation Appeal Against Teva Pharmaceuticals USA, Inc and Apotex Inc
Dec-13-2022
Lawsuits & Legal Issues
Vanda Pharmaceuticals Inc. Responds to Ruling in HETLIOZ ANDA Litigation Against Teva Pharmaceuticals USA, Inc. and Apotex Inc
Nov-28-2022
Product-Related Announcements
Apotex Inc., Launches Pre-Filled Autoinjector for Lapelga®

Competitors
Akorn Operating Company LLC, Alcon Inc. (SWX:ALC), Alvogen, Inc., Amarin Corporation plc (NasdaqGM:AMRN), American Regent, Inc., Amneal Biosciences LLC, Amneal Pharmaceuticals, Inc. (NYSE:AMRX), ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP), AstraZeneca Canada Inc., Aurobindo Pharma Limited (NSEI:AUROPHARMA), AvKARE, LLC, Bausch & Lomb Incorporated, Bayer Inc., Boehringer Ingelheim GmbH, Bristol Myers Squibb Canada Co., Cipla USA Inc., Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Limited (BSE:500124), Fresenius Kabi Aktiengesellschaft, Fresenius Kabi USA, LLC, GlaxoSmithKline Inc., Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Golden State Medical Supply, Inc., Granules India Limited (BSE:532482), Hikma Pharmaceuticals PLC (LSE:HIK), Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA Inc., Janssen Inc., Johnson & Johnson Inc., Mallinckrodt LLC, Mallinckrodt plc (OTCPK:MNKT.Q), Merck Canada Inc., Method Pharmaceuticals, LLC, Nexus Pharmaceuticals, Inc., Novartis International AG, Novartis Pharmaceuticals Canada Inc., P&L Development, LLC, Padagis LLC, Par Pharmaceutical, Inc., Perrigo Company plc (NYSE:PRGO), Pfizer Canada Inc., Pfizer Inc. (NYSE:PFE), Pharmascience Inc., Pronova BioPharma Norge AS (Acquired), Sagent Pharmaceuticals, Inc., Sandoz Canada Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), Teva Canada Limited, The Medicines Company, Valeant Canada Ltd., Viatris Inc. (NasdaqGS:VTRS), Winthrop U.S., Woodward Pharma Services LLC

M&A Advisors
ADVANT Nctm, Allen & Overy LLP, Davies Ward Phillips & Vineberg LLP, Freshfields Bruckhaus Deringer LLP, Rothschild & Co SCA (ENXTPA:ROTH), Rothschild (Canada) Holdings Inc., Rothschild Canada Inc.


Advisors
M&A Advisors
ADVANT Nctm, Allen & Overy LLP, Davies Ward Phillips & Vineberg LLP, Freshfields Bruckhaus Deringer LLP, Rothschild & Co SCA (ENXTPA:ROTH), Rothschild (Canada) Holdings Inc., Rothschild Canada Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 03:35 AM
Apotex Inc.
Apotex Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
21
GlobalData

Sep 08, 2023 01:33 AM
Apotex Inc.
Apotex Inc - Strategic SWOT Analysis Review
Reports
61
GlobalData

Jun 09, 2023 06:30 AM
Apotex Inc.
Apotex Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20
GlobalData

Jun 08, 2023 02:54 AM
Apotex Inc.
Apotex Inc - Strategic SWOT Analysis Review
Reports
55
GlobalData

Mar 11, 2023 06:25 AM
Apotex Inc.
Apotex Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Mar 06, 2023 11:04 PM
Apotex Inc.
Apotex Inc - Strategic SWOT Analysis Review
Reports
56
GlobalData

Dec 09, 2022 10:19 PM
Apotex Inc.
Apotex Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Dec 09, 2022 02:03 AM
Apotex Inc.
Apotex Inc - Strategic SWOT Analysis Review
Reports
56
GlobalData

Sep 15, 2022 06:15 AM
Apotex Inc.
Apotex Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
GlobalData

Sep 12, 2022 04:38 AM
Apotex Inc.
Apotex Inc - Strategic SWOT Analysis Review
Reports
58


Projects Summary
Project Name
Company Role
Project Status
Date Created
Last Updated
Deal Size($mm)
Project Raven
Target
Research
Jun-24-2020
Jul-06-2020
-


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Amlodipine Besylate Tablets, Apo Triavir, Apo-Atorvastatin, Apo-Esomeprazole, Apo-Latanoprost, Coreg, G-CSF (Future), Neukine (Future), Pharmaceutical Products, Plavix, Potassium Chloride Oral Solution USP


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-14-2015
Oct-13-2015
Apotex Inc.
SEC
8-K (8.01)
15 KB
Sep-07-2011
Sep-07-2011
Apotex Inc.
SEC
8-K (8.01, 9.01)
60 KB
Jun-25-2010
Jun-24-2010
Apotex Inc.
SEC
8-K (8.01)
25 KB
Feb-10-2010
Feb-08-2010
Apotex Inc.
SEC
8-K (8.01)
21 KB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Fahner, Gordon 
Senior Vice President of Global Finance
-
800 609 9444

McNicoll, Andrew 
Senior Vice-President of Global Quality & Compliance
-
800 609 9444

Berman, Jordan 
Vice President of Global Corporate Affairs, Business Transformation & Strategic Planning
647-272-2287
800 609 9444

Campbell, Joanne 
Senior VP & Chief Human Resources Officer
-
800 609 9444

Hardwick, Peter 
Chief Commercial Officer & Executive VP
-
800 609 9444

Krishnan, Kiran 
Senior Vice President of Global Regulatory Affairs
-
800 609 9444

Liberty, Steven M.
EVP of Global Supply & Technical Operations
-
800 609 9444

Shelley, Ray 
Senior Vice President of Commercial Operations-Canada & Caribbean
-
800 609 9444

Heselton, Mark
President of Apotex International
-
800 609 9444
-
Paton, Pere 
President of Global API
-
800 609 9444

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
